| HRA011494
(Controlled Access)
|
This multicenter, phase II trial (CHESS) evaluated the safety and efficacy of zanubrutinib plus rituximab induction therapy followed by shortened chemoimmunotherapy in previously untreated mantle cell lymphoma (MCL) patients. The results showed a high complete response (CR) rate of 88% at the completion of the induction phase, with a 2-year progression-free survival and overall survival rate of 85% and 90%, respectively. Transcriptomic analyses identified three MCL molecular subtypes with distinct treatment responses, providing insights for future personalized treatment strategies. |
